Literature DB >> 20398809

B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology.

Antonino Carbone1, Annunziata Gloghini, Antonella Aiello, Adele Testi, Antonello Cabras.   

Abstract

Published in September 2008, the updated World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues introduces provisional borderline categories for lymphoma cases that demonstrate overlapping clinical, morphological, and/or immunophenotypic features between well-established entities. These overlapping features pose real diagnostic challenges especially in identifying atypical cases of diffuse large B-cell lymphoma, Hodgkin lymphoma, and Burkitt lymphoma. Lymphoma cases showing borderline features between T-cell/histiocyte-rich large B-cell lymphoma and nodular lymphocyte predominant Hodgkin lymphoma are not included within the borderline categories provisionally recognized by the updated classification. Within the borderline categories, there are cases combining features of primary mediastinal large B-cell lymphoma and classical Hodgkin lymphoma. Many of these cases resemble classical Hodgkin lymphoma but have a large number of tumor cells expressing CD20, CD45, and B-cell transcription factors. Alternatively, these cases may resemble primary mediastinal large B-cell lymphoma but contain tumor cells resembling Reed-Sternberg cells and displaying an aberrant phenotype such as CD20(-), CD15(-/+) CD45(+), CD30(+), Pax5(+), OCT2(+/-), and BOB1(+/-). Another new borderline category defining B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, represents a biologically heterogeneous group. Cases with morphologic features intermediate and with CD10/BCL6 coexpression should be placed in diffuse large B-cell lymphoma/Burkitt lymphoma category if tumor cells also show strong BCL2 staining and/or a Ki67 proliferation index of less than 90%. When MYC rearrangements are present in these cases, the lymphomas often have atypical features, including concurrent rearrangements of BCL2 and/or BCL6 genes (so-called double/triple-hit lymphomas) and more aggressive behavior. For the provisional borderline categories, unresolved issues include understanding molecular pathogenesis and defining an effective treatment. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20398809     DOI: 10.1016/j.humpath.2009.10.027

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  15 in total

Review 1.  Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?

Authors:  Deborah A Thomas; Susan O'Brien; Stefan Faderl; John T Manning; Jorge Romaguera; Luis Fayad; Fredrick Hagemeister; Jeffrey Medeiros; Jorge Cortes; Hagop Kantarjian
Journal:  Curr Hematol Malig Rep       Date:  2011-03       Impact factor: 3.952

2.  Triple-hit lymphoma.

Authors:  Naresh Pemmaraju; Javed Gill; Saurabh Gupta; John R Krause
Journal:  Proc (Bayl Univ Med Cent)       Date:  2014-04

Review 3.  Transformation of follicular lymphoma.

Authors:  Izidore S Lossos; Randy D Gascoyne
Journal:  Best Pract Res Clin Haematol       Date:  2011-05-06       Impact factor: 3.020

4.  MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies.

Authors:  Ronit Vogt Sionov
Journal:  ISRN Hematol       Date:  2013-01-29

5.  A case of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma in a Korean child.

Authors:  Jeong Yeal Ahn; Yiel Hea Seo; Pil Whan Park; Kyung Hee Kim; Mi Jung Park; Ji Hoon Jeong; Soon Ho Park; Young Hee Song
Journal:  Ann Lab Med       Date:  2012-02-23       Impact factor: 3.464

Review 6.  Aggressive B-cell lymphomas: how many categories do we need?

Authors:  Jonathan W Said
Journal:  Mod Pathol       Date:  2012-11-16       Impact factor: 7.842

7.  Clinicopathological Analysis of B Cell Lymphomas, Unclassifiable; with Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma in a Tertiary Care Hospital in Southern India.

Authors:  Subramanian Kalaivani Selvi; Rakhee Kar; Debdatta Basu; Sajini Elizabeth Jacob; Biswajit Dubashi
Journal:  Indian J Hematol Blood Transfus       Date:  2015-05-30       Impact factor: 0.900

8.  Micro-RNA Expression and Function in Lymphomas.

Authors:  Sukhinder K Sandhu; Carlo M Croce; Ramiro Garzon
Journal:  Adv Hematol       Date:  2011-03-22

9.  Recent Advances in the Pathobiology of Hodgkin's Lymphoma: Potential Impact on Diagnostic, Predictive, and Therapeutic Strategies.

Authors:  Diponkar Banerjee
Journal:  Adv Hematol       Date:  2011-01-18

10.  Biostable ssDNA aptamers specific for Hodgkin lymphoma.

Authors:  Parag Parekh; Sanchit Kamble; Nianxi Zhao; Zihua Zeng; Jianguo Wen; Bin Yuan; Youli Zu
Journal:  Sensors (Basel)       Date:  2013-10-25       Impact factor: 3.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.